Skip to main content

HalioDx Inks Israeli Distribution Deal for Colon Cancer Assay

NEW YORK (360Dx) — HalioDx announced today that it has signed a distribution agreement for its Immunoscore colon cancer assay in Israel with Pronto Diagnostics.

Immunoscore Colon, which was CE-IVD marked in early 2017, is designed to quantify CD3+ and CD8+ cell infiltrates in the core tumor and its invasive margin to determine the likelihood cancer will spread or recur after surgery. The assay is performed on formalin-fixed, paraffin-embedded tissue from tumor resections or tumor biopsies, and combines immunohistochemistry with a high-resolution image analysis system.

Under the terms of the deal, the test will be marketed in Israel by pharmaceutical firm CTS through an alliance with Pronto. Additional terms were not disclosed.

Earlier this month, HalioDx signed on Sohin as the exclusive distributor of Immunoscore Colon in Mexico. HalioDx also recently closed a €18.5 million ($21.7 million) Series B financing round and said it intends to use the proceeds to continue development of Immunoscore Colon and other Immunoscore assays, as well as establish US operations.